AzTrials
AzTrials

InsomniaNCT06541886

Adapted CBT-I for Adolescents With Insomnia : The DREAM-IT Study

A study testing Cognitive Behavioral Therapy for Insomnia (CBT-I) in people with Insomnia, run by Indiana University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to test an adapted treatment for teen insomnia in comparison to a waitlist condition. Cognitive Behavioral Therapy for Insomnia (CBT-I) is an intervention that was developed for adults and is sometimes also used for teens. Read more about this study

Who is it for?
Ages 13 to 18 years
Conditions the study is for
Insomnia
What is being tested?
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
1 siteUnited States
Study dates
3 Apr 2025to Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Adolescents (13-18 years) who are in either middle school or high school and meet ICSD-3 diagnostic criteria for Chronic Insomnia Disorder, currently or in the past year, based on self-reported insomnia symptoms, using a screening checklist.
  • Reside in a state where Dr. McQuillan (supervising provider) is licensed to practice psychology (with PsyPact) which are the following states: Alabama, Arizona, Arkansas, Colorado, Commonwealth of the Northern Mariana Islands, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
  • Sufficient English language proficiency for consent and study participation
  • Reliable internet access to attend virtual visits with audio and video
  • Parents or other caregivers of these adolescents (hereafter referred to as a parent) must live in the home with the identified adolescent at least 50% of the time and must report playing a parental role for that adolescent. The parent must also be able to attend the final 10 minutes of each treatment session, if the teen is randomized to a treatment condition.

Who cannot join

  • Sleep aid use that is either inconsistent (e.g., used some but not all nights) and cannot be discontinued OR consistent and effective enough that the teen no longer has insomnia symptoms while using it. If a teen agrees to keep the dose and frequency of sleep aid use consistent throughout the treatment and still has insomnia symptoms at baseline, they are not ineligible.
  • Prior participation in Aim 1 of DREAM IT study (e.g., participation in an Aim 1 focus group).
  • Comorbid medical or psychiatric conditions, including substance use disorders, that are acute, unstable, or untreated. Individuals with Autism Spectrum Disorder, Epilepsy, Schizophrenia, and Bipolar Disorder will be excluded.
  • Comorbid delayed sleep wake phase disorder or other active/untreated sleep disorders, including RLS, OSA, and Nightmare disorder
  • Active suicidal ideation with plan and intent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Maureen E McQuillan, PhD contact

317-944-7368

memcquil@iu.edu

Sarah M Honaker, PhD contact

317-278-0570

smhonake@iu.edu

United States1 site, 1 recruiting
  • Indiana University School of Medicine

    Indianapolis, Indiana, 46220

    Maureen E McQuillan, PhD

    Recruiting

Other trials in United States

About this study

The goal of this study is to test an adapted treatment for teen insomnia in comparison to a waitlist condition. Cognitive Behavioral Therapy for Insomnia (CBT-I) is an intervention that was developed for adults and is sometimes also used for teens. Teens, parents, and health care providers helped to review and adapt CBT-I to form Teen CBT-I. Teen CBT-I includes most of the same content as CBT-I, with some changes to match teen biology and lifestyles.

The main questions this clinical trial aims to answer are:

Read more
  • Does Teen CBT-I improve insomnia symptoms in teens?
  • Researchers will compare Teen CBT-I to the waitlist control condition to see if insomnia symptoms significantly improve in the treatment group.
  • Do teens and their parents find Teen CBT-I to be acceptable? o Researchers will examine Teen CBT-I acceptability ratings.

Teen CBT-I is hypothesized to improve insomnia symptoms in teens, and teens and parents are hypothesized to find Teen CBT-I to be acceptable.

Teen participants will be randomized to one of the two conditions: Teen CBT-I treatment or waitlist control. They will also complete assessments at three timepoints: Baseline (before treatment); post-intervention (after treatment); and follow-up (2 months after treatment). For each assessment, teen participants will:

  • Fill out questionnaires about their sleep, mood, and other areas
  • Keep daily sleep logs for one week
  • Wear an actigraph, a wrist-watch like device that records activity levels to determine sleep-wake patterns, for one week.

Parent participants will also be asked to complete questionnaires at each measurement point about their teen's sleep, mood, and other areas.

The intervention conditions are:

  • Teen CBT-I includes 4-6 one-hour individual virtual sessions with a therapist. It includes standard CBT-I content with some small changes to match teen biology and lifestyles. The main parts of this treatment include healthy sleep habits, only using the bed for sleep, keeping a recommended sleep schedule, changing negative thoughts about sleep, and learning ways to relax the mind and body for sleep.
  • Waitlist-control, in which teens will not receive any treatment for 8 weeks. After the second assessment, they will receive free access to an app-based CBT-I treatment which they can complete on their own.
Read the detailed description

Background: Cognitive Behavioral Therapy for Insomnia (CBT-I) has been well-established as an efficacious and first-line treatment for insomnia in adults, but research on its use with adolescents is limited. Preliminary evidence for the efficacy of CBT-I with adolescents is promising, but treatment protocols in existing trials are heterogeneous, making it difficult to characterize CBT-I for teens. In Aim 1 of this study, CBT-I was systematically adapted through collaboration with stakeholders (i.e., teens, parents, and behavioral sleep medicine providers across the country), making changes to the intervention tailored to teen biology and lifestyles.

Objective: The objective of this study is to test this adapted intervention (hereafter referred to as Teen CBT-I) in comparison to a waitlist control condition in adolescents with insomnia.

Hypotheses:

  1. Teen CBT-I will reduce insomnia symptoms compared to a no treatment (waitlist) condition.
  2. Teen CBT-I will be deemed acceptable by teens and parents.

Participants: Adolescents with insomnia (N=28) and their parents will be randomized to either Teen CBT-I (n=14) or the waitlist control condition (n = 14).

Recruitment: Parents of adolescents are recruited primarily via social media. Recruitment posts and images are boosted to both Facebook and Instagram using the Facebook Ads Manager system. We also advertise our study on Research Match and All IN for Health TrialX iConnect.

ResearchMatch.org is a national electronic, web-based recruitment tool that was created through the Clinical \& Translational Science Awards Consortium in 2009 and is maintained at Vanderbilt University Medical Center. There is no cost for researchers at participating institutions in the ResearchMatch Network to use ResearchMatch for the purposes of conducting recruitment feasibility analysis or participant recruitment. The Vanderbilt University Medical Center IRB provides oversight for ResearchMatch as a recruitment tool.

iConnect is a HIPAA-compliant and secure public facing research recruitment platform provided by the Indiana Clinical and Translational Sciences Institute (Indiana University) consisting of a study trial listing and volunteer registry. This system is licensed by Indiana University from TrialX and is monitored by the Indiana University Information Technology Services (UITS) and University Information Security Office (ISO). Study Teams have access to their study listings and participant referrals based on a secure login. There is a small Administrative Team within the Indiana CTSI that manages the iConnect platform and has access to all study information, referrals, and registry volunteers. This online platform provides researchers with the ability to create a public facing webpage that can contain a brief prescreener and the ability for the public to refer themselves to the trial.

Across social media, research match, and All in for Health, recruitment posts and images describe the study and provide a link to an Interest Survey for parents to complete. Parents can then provide consent and contact information for their teen to also be contacted and invited to complete a recruitment survey.

Interest Survey:

The online surveys will provide additional information about the study and ask eligibility questions. Ineligible respondents will be informed of their status and will not be asked for any additional information. Respondents who are not ineligible* will be asked for contact information and demographic information.

Some, but not all, interested participants will be contacted and invited to complete the next step, an Eligibility and Consent Meeting.

*Some eligibility criteria will be assessed during the Eligibility and Consent meeting as they are more complex and require evaluation through an interactive call rather than a survey.

Eligibility and Consent Meeting:

Parent-teen dyads who completed the recruitment surveys and are not screened out will then be asked to meet with a research team member to further determine eligibility. Teen suicidal ideation will be evaluated, along with other comorbid conditions that may make the teen ineligible.

If the teen and parent are determined to be eligible for the study, an informed consent process will then be initiated. Parents and teens will be provided with more information about the study and the opportunity to ask questions, prior to deciding whether or not they would like to be part of the study. Enrolled participants will then proceed to the baseline assessment.

Randomization Once the baseline measures are completed, the teen-parent dyad will be randomized to one of the two conditions using a randomization module in REDCap. Randomization will be stratified based on age so that there is the same number of younger teens (ages 13-15) and older teens (ages 16-18) in each condition.

Conditions Participants randomized to Teen CBT-I will meet individually with a therapist for a virtual, one-hour session. Each session will be administered free of charge. Most of each treatment session will be with just the therapist and the teen. However, the parent will be asked to join for the last ten minutes of each appointment to keep the parent informed about the treatment plan. If they wish, teens can decide to involve their parent earlier in the session.

Teen CBT-I Teens in this treatment condition will have an intake session and between 4 to 6 treatment sessions. The first session will include an introduction to sleep science and insomnia treatment. Middle sessions will include Healthy sleep habits, Setting a sleep schedule, Preparing the mind and body for sleep, and Distinguishing the sleep space from the teen's hang out space. The last session will be centered on maintenance of treatment gains. Treatment will include visual aids (e.g., a powerpoint) to convey didactic or psychoeducational material.

Waitlist Control Teens in the waitlist condition will still complete the same study measures, but they will not receive treatment from a therapist. Their treatment will begin after they have completed the second round of measures (i.e., 8 weeks after completing the baseline measures). After they have completed the second round of measures, they will be given free access to an app that provides guided insomnia treatment. While no live therapist is involved, the approach is similar to traditional CBT-I.

Fidelity Monitoring Audio and video will be recorded during the treatment sessions. The purpose of this is so that supervisors can review some of the sessions to help with therapist training, and to make sure that the therapist is following the treatment protocol. These recordings will only be reviewed by the study team to monitor the therapist, and recordings will be stored securely. No one outside of the study will have access to these recordings. The recordings will be deleted after the 2-month follow up. De-identified (i.e., without names, location) transcripts of the sessions will be kept. If a teen-parent dyad is not comfortable with recording of the sessions, they can opt out, meaning that they can still be in the study, but their treatment sessions will not be recorded. There is an opt-in / opt-out component within the informed consent process.

Analysis Plan Linear regression modeling will be used to assess pre- and post-intervention changes in clinical outcomes, reporting effect sizes (Cohen's d) and controlling for relevant covariates.

Implementation outcomes will be reported descriptively. With n=28 (comparing two groups in multiple pairwise comparisons), 80% power, and α = .05, there is adequate power to detect an effect size of d = 1.00, which is consistent with prior research testing CBT-I for teens and adults, with effect sizes ranging from d = 1.00-1.22.

Potential Risks Potential risks include confidentiality breaches and discomfort from wearing the actigraph, a wrist-watch like device that will be used to measure adolescent sleep outcomes.

The risk of loss of confidentiality will be minimized by the research team. Efforts will be made to keep personal information confidential, and only de-identified group data will be shared or published to keep participant identity confidential. Personal information would only be disclosed if required by law.

Completed questionnaires will be stored in a secure, electronic database that is accessible only by study team members approved by the Office for Protection of Human Subjects.

One exception to confidentiality would be if there is concern about the health and safety of a teen. This risk would be immediately discussed with the teen and parent and reported to the necessary authorities to ensure safety. An example of this would be if a teen indicated they were being abused or that they were planning to hurt themselves or someone else.

Another exception to confidentiality is that the university and federal offices that are in charge of protecting the rights of research participants and the quality of research may, in rare instances, need to inspect or copy a researcher's data. This includes the Indiana University Institutional Review Board and the Office for Human Research Protections.

Although extremely rare, if a participant experiences skin discomfort from the actigraph, they can wear the device over a shirt.

It is also possible that participants could lose or damage the actigraph. Research staff will explain the proper use and importance of these devices to prevent such risks, but the risk is still possible. If a participant loses or damages the actigraph, they will not be held financially responsible and will not be excluded from the study. Data within the actigraph can only be accessed with specialized software. In addition, no identifiers are included in the actigraphic output aside from the participant's research ID.

Informed consent. The process will be conducted in a location that is considered private and controlled. The consenting process will include the study purpose, inclusion/exclusion criteria, enrollment goal, timeline and study interventions. The adolescent participant will assent for the study following IRB guidelines along with obtaining consent from adult participants. All participants will be asked to provide verbal consent/assent prior to participation in any study activities or interventions.

Potential benefits of the proposed research to human subjects and others Benefits to participants may include improvement in insomnia symptoms. The potential benefit to society is determining whether the adapted treatment protocol is efficacious. If it is, it can then be used more widely to improve outcomes for adolescents with insomnia. This can lead to improved functioning in adolescents with insomnia and intervention success for providers and caregivers.

Conditions
Insomnia
Being tested
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Keywords
Cognitive Behavioral Therapy for Insomnia, Adolescence, Randomized controlled trial, Efficacy, Stakeholders, Adaptation, Actigraphy
Medical subject headings
Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Behavioral Therapy for Insomnia (CBT-I)Behavioural

    CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.

Study groups in NCT06541886
Study groupRoleWhat they receive
Teen CBT-IExperimentalTeens in this treatment condition will have an intake session and 6 treatment sessions virtually and individually with a therapist. The first session will include an introduction to Sleep Science and Insomnia Treatment. Middle sessions will include Healthy Sleep Habits, Setting a Sleep Schedule, Preparing the Mind and Body for Sleep, and Distinguishing the Sleep Space and Wake Space. The final session will be be centered on maintenance of treatment gains. Treatment will also include visual aids (e.g., slides) to convey didactic or psychoeducational material.
Receives: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)
WaitlistNo interventionTeens in the waitlist condition will still complete the same study measures and receive the same payment for taking part in the study, but they will not receive treatment from a therapist. Their treatment will begin after they have completed the second round of measures (i.e., 8 weeks after they complete the baseline assessment). After they have completed the second round of measures, they will be given free access to an app that provides guided insomnia treatment. While no live therapist is involved, the approach is similar to traditional CBT-I.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Teen-reported insomnia severity

    assessed via the PROMIS (Patient-Reported Outcomes Measurement Information System) sleep disturbance scale, which has been established as reliable and valid with adolescents. Possible scores on this scale range from 10 - 50, where higher scores reflect more severe insomnia.

    Measured: Baseline, Post-treatment (approximately 8 weeks after baseline), and 2 month follow up

  2. Teen-reported treatment acceptability

    based on the widely used Client Satisfaction Questionnaire, which assesses treatment feasibility, satisfaction, and perceived helpfulness. Possible scores on this scale range from 8-40, where higher scores reflect higher acceptability ratings.

    Measured: Post-treatment (approximately 8 weeks after baseline)

Secondary outcomes (20)
  1. Teen-reported sleep onset latency

    Based on sleep diary

    Measured: Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  2. Teen-reported wake after sleep onset

    Based on sleep diary

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  3. Teen-reported night wakings

    Number of night wakings, based on sleep diary

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  4. Teen-reported sleep efficiency

    Average of total sleep time divided by time spent in bed each night, based on information provided by teen in the sleep diary

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  5. Sleep efficiency

    Average of total sleep time divided by time spent in bed each night, as measured via the actigraph

    Measured: assessed at Baseline and Post-treatment (approximately 8 weeks after baseline)

  6. Wake after sleep onset

    Based on actigraphy

    Measured: assessed at Baseline and post-treatment (approximately 8 weeks after baseline)

  7. Teen Mood

    Depressive Symptoms from the PROMIS (Patient-Reported Outcomes Measurement Information System) measure. Possible scores range from 8 to 40, where higher scores reflect more depressive symptoms.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  8. Teen Stress

    Teen report on the PROMIS (Patient-Reported Outcomes Measurement Information System) Psychological Stress Experiences measure. Possible scores range from 8 to 40, where higher scores reflect more stress.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  9. Teen Daytime Sleepiness

    Teen report on the PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-Related Impairment Scale. Possible scores range from 8 to 40, where higher scores reflect more daytime impairment.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  10. Teen-reported sleep hygiene

    pediatric sleep practices questionnaire - short form. Possible scores range from 7 to 35, where higher scores reflect better sleep hygiene.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  11. Teen-reported parent-teen conflict about sleep

    "How much did you and your parent argue about sleep in the past week ?" Using a 1-5 Likert scale, where higher scores reflect more conflict.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  12. Parent-reported parent-teen conflict about sleep

    "How much did you and your teen argue about sleep in the past week ?" Using a 1-5 Likert scale, where higher scores reflect more conflict.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  13. Parent-reported insomnia symptoms

    using the parent-report PROMIS (Patient-Reported Outcomes Measurement Information System) sleep disturbance scale. Possible scores range from 10 - 50, where higher scores reflect more severe insomnia.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  14. Parent-reported daytime sleepiness

    using the parent-report PROMIS (Patient-Reported Outcomes Measurement Information System) sleep related impairment scale. Possible scores range from 8 to 40, where higher scores reflect more severe daytime impairment.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  15. Parent perception of adolescent mood

    using the parent-report PROMIS (Patient-Reported Outcomes Measurement Information System) depressive symptoms scale. Possible scores range from 6 to 30, where higher scores reflect more teen depressive symptoms.

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  16. Parent-reported school attendance

    Based on two items: "In the past 2 weeks, how many days has your child missed school because of difficulty sleeping?" AND "In the past 2 weeks, how many days has your child been late to school because of difficulty sleeping?"

    Measured: assessed at Baseline, Post-treatment (approximately 8 weeks after baseline), and at 2-month follow up

  17. Teen-reported treatment adherence

    via adolescent report on sleep diary

    Measured: assessed at Post-treatment (approximately 8 weeks after baseline) and at 2-month follow up

  18. Treatment engagement

    based on session attendance and treatment completion

    Measured: assessed at post-treatment approximately 8 weeks after baseline

  19. Adverse treatment effects

    Report of any car accidents, suicidality, or risky behaviors that could be attributed to sleep restriction and/or reductions in daytime alertness

    Measured: assessed at post-treatment approximately 8 weeks after baseline

  20. Parent-reported treatment acceptability

    based on the widely used Client Satisfaction Questionnaire, which assesses treatment feasibility, satisfaction, and perceived helpfulness. Possible scores on this scale range from 8-40, where higher scores reflect higher acceptability ratings.

    Measured: assessed at post-treatment approximately 8 weeks after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2024
  2. Study start3 Apr 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study has a parallel intervention study model. Participants are assigned to one of two groups in parallel for the duration of the study-either Teen CBT-I or waitlist control for 8 weeks.
Masking
None (open label)
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06541886
Sponsor's protocol ID
13047
Other IDs
249-SR-21
Status last verified
May 2026
First submitted
23 Jul 2024
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive Behavioral Therapy for Insomnia (CBT-I) in people with Insomnia, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maureen E McQuillan, PhD (317-944-7368, memcquil@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Teen-reported insomnia severity (time frame: Baseline, Post-treatment (approximately 8 weeks after baseline), and 2 month follow up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in